Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy

被引:32
作者
Siebenhofer, A
Plank, J
Berghold, A
Horvath, K
Sawicki, PT
Beck, P
Pieber, TR
机构
[1] Leopold Auenbrugger Univ Hosp, Med Univ, Dept Internal Med, Div Diabet & Metab, A-8036 Graz, Austria
[2] Med Univ, Inst Med Informat Stat & Documentat, Graz, Austria
[3] St Franziskus Hosp, Dept Internal Med, Cologne, Germany
[4] Inst Evidence Based Med, Cologne, Germany
[5] Inst Med Technol & Hlth Management, Joanneum Res, Graz, Austria
关键词
complications; continuous subcutaneous insulin infusion; diabetes mellitus; hypoglycaemia; intensified insulin therapy; meta-analysis; randomized controlled trial;
D O I
10.1007/s00125-004-1545-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis. This study aimed to compare the effect of treatment with short-acting insulin (SAI) analogues versus structurally unchanged short-acting insulin (regular insulin) on glycaemic control and on the risk of hypoglycaemic episodes in type I diabetic patients using different insulin treatment strategies. Methods. We performed a meta-analysis of 27 randomised controlled trials that compared the effect of SAI analogues with regular insulin in patients with type I diabetes mellitus. The treatments were administered either via continuous subcutaneous insulin infusion (CSII) or by conventional intensified insulin therapy (IIT) with short-acting insulin injections-before meals and basal insulin administered once or twice daily in most cases. Results. HbA(1)c levels were reported for 20 studies. For studies using CSII, the weighted mean difference between values obtained using SAI analogues and regular insulin was -0.19% (95% Cl: -0.27 to 0.12), whereas the corresponding value for injection studies was -0.08% (95% Cl: -0.15 to -0.02). For the analysis of overall hypoglycaemia, we used the results from nine studies that reported the mean frequency of hypoglycaemic episodes per patient per month. For studies using CSII, the standardised mean difference between SAI analogues and regular insulin was -0.07 (95% Cl: -0.43 to 0.28), whereas for IIT studies the corresponding value was -0.04 (95% Cl: -0.24 to 0.16). Conclusions/interpretation. Taking into consideration the low quality of the trials included, we can conclude that use of a short-acting insulin analogue in CSII therapy provides a small, but statistically significant improvement in glycaemic control compared with regular insulin. An even smaller effect was obtained with the use of ITT. The rate of overall hypoglycaemic episodes was not significantly reduced with short-acting insulin analogues in either injection regimen.
引用
收藏
页码:1895 / 1905
页数:11
相关论文
共 64 条
[1]   Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus [J].
Anderson, JH ;
Brunelle, RL ;
Keohane, P ;
Koivisto, VA ;
Trautmann, ME ;
Vignati, L ;
DiMarchi, R .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (11) :1249-1255
[2]   Improved mealtime treatment of diabetes mellitus using an insulin analogue [J].
Anderson, JH ;
Brunelle, RL ;
Koivisto, VA ;
Trautmann, ME ;
Vignati, L ;
DiMarchi, R ;
Cameron, DP ;
Yeu, DK ;
Zimmet, P ;
Lauvaux, JP ;
VanGaal, LF ;
Chiasson, JL ;
Fettes, IM ;
Tan, MH ;
Toth, EL ;
Charbonnel, B ;
Selam, JL ;
Haslbeck, M ;
SchulzeSchleppinghoff, B ;
Karasik, A ;
Hazenberg, HJ ;
VanDoorn, LG ;
Bonnici, FB ;
Hough, S ;
Mollentze, WF ;
Moore, R ;
Omar, MA ;
Robertson, LI ;
VanRooyen, RJ ;
DeLeiva, A ;
Jara, A ;
Vazquez, JA ;
Arslanian, S ;
Bastyr, EJ ;
Bergenstal, RM ;
Blonde, L ;
Boyce, PA ;
Chase, HP ;
Clarke, DH ;
Davidson, J ;
Garber, A ;
Goldberg, RB ;
Guthrie, RA ;
Mayfield, RK ;
Mengel, MC ;
Prince, MJ ;
Reeves, ML ;
Rosenzweig, JL ;
Schade, DS ;
Soeldner, JS .
CLINICAL THERAPEUTICS, 1997, 19 (01) :62-72
[3]   Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment [J].
Anderson, JH ;
Brunelle, RL ;
Koivisto, VA ;
Pfutzner, A ;
Trautmann, ME ;
Vignati, L ;
DiMarchi, R ;
Bowen, KM ;
Cameron, DP ;
Nankervis, AJ ;
Roberts, AP ;
Zimmet, P ;
Borkenstein, MH ;
Schernthaner, G ;
Waldhausl, WK ;
DeLeeuw, IH ;
Fery, F ;
Scheen, A ;
Somers, G ;
Fettes, IM ;
Tildesley, HD ;
Toth, EL ;
Viikari, J ;
Altman, JJ ;
Bougneres, PF ;
Drouin, P ;
Fossati, P ;
Guillausseau, PJ ;
Marechaud, E ;
Riou, JP ;
Selam, JL ;
Vialettes, PB ;
Beyer, J ;
Federlin, K ;
Fussganger, RD ;
Gries, FA ;
Jastram, HU ;
Koop, I ;
Landgraf, R ;
Rosak, C ;
Schatz, H ;
SchulzeSchleppinghoff, B ;
Seif, FJ ;
Stoeckmann, F ;
Karasik, A ;
Weitzman, S ;
Andreani, D ;
Bompiani, G ;
Crepaldi, G ;
Giorgino, R .
DIABETES, 1997, 46 (02) :265-270
[4]  
Annuzzi G, 2001, NUTR METAB CARDIOVAS, V11, P168
[5]   Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion - A randomized study in type 1 diabetes [J].
Bode, B ;
Raskin, P ;
Weinstein, R ;
Davidson, J ;
Bell, D ;
Henry, R ;
McGill, J ;
Huang, WC ;
Nadeau, D ;
Reinhardt, RR .
DIABETES CARE, 2002, 25 (03) :439-444
[6]   Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes [J].
Bode, BW ;
Strange, P .
DIABETES CARE, 2001, 24 (01) :69-72
[7]   Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients [J].
Boehm, BO ;
Home, PD ;
Behrendt, C ;
Kampt, NM ;
Lindholm, A .
DIABETIC MEDICINE, 2002, 19 (05) :393-399
[8]   Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes [J].
Bott, U ;
Ebrahim, S ;
Hirschberger, S ;
Skovlund, SE .
DIABETIC MEDICINE, 2003, 20 (08) :626-634
[9]   Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime [J].
Ciofetta, M ;
Lalli, C ;
Del Sindaco, P ;
Torlone, E ;
Pampanelli, S ;
Mauro, L ;
Chiara, D ;
Brunetti, P ;
Bolli, GB .
DIABETES CARE, 1999, 22 (05) :795-800
[10]   Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes [J].
Cryer, PE .
DIABETOLOGIA, 2002, 45 (07) :937-948